bepotastine besilate 15 MG/ML Ophthalmic Solution [Bepreve]
bepotastine besilate
RxCUI: 863042
What the CMS Formulary Data Shows for bepotastine besilate 15 MG/ML Ophthalmic Solution [Bepreve]
Per the CMS 2026 Part D formulary file, bepotastine besilate 15 MG/ML Ophthalmic Solution [Bepreve] (RxNorm concept RXCUI 863042, generic name bepotastine besilate) appears on 4 distinct formulary files spanning 775 Medicare Part D plan offerings - 15.3% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 4 to Tier 4, with a cross-plan average of Tier 4.
Real-world access to bepotastine besilate 15 MG/ML Ophthalmic Solution [Bepreve] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 19,677 Part D beneficiaries filled bepotastine besilate 15 MG/ML Ophthalmic Solution [Bepreve] in 2023, with total plan-and-beneficiary spending of $14,858,515 and an average per-beneficiary annual cost of $755.12. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry bepotastine besilate 15 MG/ML Ophthalmic Solution [Bepreve] today.
Coverage Details
- Formularies covering
- 4
- Plans covering
- 775
- Coverage rate
- 15.3%
- Tier range
- Tier 4, Non-Preferred
- Average tier
- Tier 4, Non-Preferred
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 0% of formularies
2023 Medicare Spending
- Beneficiaries
- 19,677
- Total spending
- $14,858,515
- Avg per beneficiary
- $755.12
Tier Distribution Across Plans
Standalone Drug Plans (PDP) Covering bepotastine besilate 15 MG/ML Ophthalmic Solution [Bepreve]
2 standalone prescription drug plans include this drug.
| Plan | Insurer | Tier | PA | ST | Premium | States |
|---|---|---|---|---|---|---|
| AARP Medicare Rx Preferred from UHC (PDP) | UNITEDHEALTHCARE INS. CO. & UHC INS. CO. OF NY | T4 | No | No | $0 | - |
| AARP Medicare Rx Preferred from UHC (PDP) | UNITEDHEALTHCARE INS. CO. & UHC INS. CO. OF NY | T4 | No | No | $0 | - |
Medicare Advantage Plans (MA-PD) Covering bepotastine besilate 15 MG/ML Ophthalmic Solution [Bepreve]
98 Medicare Advantage plans with Part D drug coverage include this drug.
Frequently Asked Questions
Is bepotastine besilate 15 MG/ML Ophthalmic Solution [Bepreve] covered by Medicare Part D?
Yes, bepotastine besilate 15 MG/ML Ophthalmic Solution [Bepreve] is covered by 775 Medicare Part D plans (15.3% of all Part D formularies).
What tier is bepotastine besilate 15 MG/ML Ophthalmic Solution [Bepreve] on Medicare Part D plans?
bepotastine besilate 15 MG/ML Ophthalmic Solution [Bepreve] averages Tier 4 across Part D plans, ranging from Tier 4 to Tier 4.
Does bepotastine besilate 15 MG/ML Ophthalmic Solution [Bepreve] require prior authorization?
0% of Part D formularies require prior authorization for bepotastine besilate 15 MG/ML Ophthalmic Solution [Bepreve]. Step therapy: 0%. Quantity limits: 0%.
How much does Medicare spend on bepotastine besilate 15 MG/ML Ophthalmic Solution [Bepreve]?
In 2023, total Medicare Part D spending on bepotastine besilate 15 MG/ML Ophthalmic Solution [Bepreve] was $14,858,515, covering 19,677 beneficiaries. The average spend per beneficiary was $755.12.
Read our methodology - how this data is sourced, computed, and verified.